Quick Answer
OCULAR THERAPEUTIX, INC reported Cash and Equivalents of $737.06 million for fiscal year 2025.
OCULAR THERAPEUTIX, INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $737.06M | +88.0% |
| 2024 | $392.10M | +100.2% |
| 2023 | $195.81M | +91.4% |
| 2022 | $102.30M | -37.7% |
| 2021 | $164.16M | -28.0% |
| 2020 | $228.06M | +318.9% |
| 2019 | $54.44M | +0.7% |
| 2018 | $54.06M | +30.2% |
| 2017 | $41.54M | +26.1% |
| 2016 | $32.94M | +7.0% |
| 2015 | $30.78M | -17.7% |
| 2014 | $37.39M | +113.6% |
| 2013 | $17.50M | -26.6% |
| 2012 | $23.85M | +347.5% |
| 2011 | $5.33M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $344.77M | -19.3% | -11.9% |
| June 30, 2025 | $391.13M | -14.9% | +11.9% |
| March 31, 2025 | $349.68M | -27.6% | -10.8% |
| December 31, 2024 | $392.10M | +100.2% | -8.2% |
| September 30, 2024 | $427.22M | +286.4% | -7.1% |
| June 30, 2024 | $459.69M | +590.2% | -4.8% |
| March 31, 2024 | $482.89M | +511.0% | +146.6% |
| December 31, 2023 | $195.81M | +91.4% | +77.1% |
- OCULAR THERAPEUTIX, INC showed an increase of +88.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, OCULAR THERAPEUTIX, INC’s cash and equivalents has grown by 13728.5% (from $5.33 million to $737.06 million).
- The most recent figure is from OCULAR THERAPEUTIX, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: